Driving Innovation: Drug Patents vs. Prizes
Part I: The Innovation Imperative: Charting the Course of Pharmaceutical R&D Introduction: The $2 Trillion Question In the sprawling, high-stakes […]
Driving Innovation: Drug Patents vs. Prizes Read Post »
July 2018
The Repositioning Revolution: Transforming Patent Data into Pharmaceutical Competitive Advantage
Section I: The Strategic Imperative of Drug Repositioning 1.1 Beyond Serendipity: The Evolution from Accidental Discovery to Deliberate Strategy Drug
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All
Executive Summary The anticipated “patent cliff” for Pfizer’s blockbuster drug, Viagra (sildenafil citrate), did not result in the typical rapid,
Viagra’s Generic Cliff: Why It Wasn’t a Free-for-All Read Post »
Generic Drug Launch Dates – A 1-step Solution to Navigate the Web of Drug Patents and Regulatory Protections
Drugs can have many patents and regulatory protections Drugs can be covered by myriad patents and regulatory protections. Even Aspirin,
Biosimilars in East & Southeast Asia: A Strategic Guide to Japan, South Korea, and Malaysia
Introduction: The New Epicenter of the Global Biosimilar Revolution The Shifting Tectonic Plates of Biopharma The global pharmaceutical landscape is
